Omicron variant: Rappuoli, third dose should have us covered

"With the third dose we should reach enough antibody levels to be able to cover this variant as well."

This was stated by scientist Rino Rappuoli, global research leader Gsk and scientific coordinator of Mad Lab at Toscana Life Sciences, regarding the effectiveness that monoclonal antibodies and vaccines on the Omicron variant can have.

Now "we know that the third dose is essential for long-lasting immunity and to cover the variants, in a year we will see if there will be a need for a fourth or fifth dose. It depends on how we vaccinate the rest of the world. In Africa just 6% of the population is vaccinated ".